1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna starts trial for Omicron-specific booster shot

01/26/2022 | 06:19pm EDT
FILE PHOTO: Illustration of COVID-19 vaccine vial

Jan 26 (Reuters) - Moderna Inc said on Wednesday it had started a mid-stage study, testing a booster dose of its COVID-19 vaccine specifically designed to target the Omicron coronavirus variant, a day after rival Pfizer Inc launched a similar trial.

The company said while a third shot of its original coronavirus vaccine increased neutralizing antibodies against the variant at the lower dose, their levels declined six months after the booster dose was administered.

However, neutralizing antibodies remained detectable in all participants, Moderna said.

While studies have indicated that Omicron results in a less severe COVID-19 than seen during previous waves, the variant has quickly become dominant in many parts of the world, driving up infections and straining healthcare systems.

The variant currently accounts for 99.9% of the COVID-19 cases in the Unites States.

Pfizer and its partner BioNTech started a clinical trial on Tuesday to test a new version of their vaccine specifically tailored to the Omicron variant.

Moderna said it would study its Omicron-specific booster in adults aged 18 years and older.

It would test the booster in individuals who received only the two-dose primary series of Moderna's original vaccine, mRNA-1273, and also in those who received the primary series and a booster dose of the same vaccine, the company said.

Moderna plans to enroll about 300 participants in each of the two groups in the study.

Three studies, led by the U.S. Centers for Disease Control and Prevention have shown that a third dose of an mRNA vaccine, such as those from Pfizer and Moderna, is key to fighting the Omicron variant.

Some countries have already started offering additional booster doses, but a recent study from Israel showed that while a fourth dose of an mRNA vaccine boosted antibodies, the level was not high enough to prevent an Omicron infection.

(Reporting by Amruta Khandekar; Editing by Devika Syamnath and Sherry Jacob-Phillips)

© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE -5.34% 154.5 Delayed Quote.-36.69%
MODERNA, INC. -4.04% 132.06 Delayed Quote.-48.00%
PFIZER, INC. 1.00% 53.41 Delayed Quote.-9.55%
All news about MODERNA, INC.
12:25pModerna's CEO Stephane Bancel to Exercise Shares, Intends to Donate Proceeds to Charity
12:13pGLOBAL MARKETS LIVE : Broadcom, Airbnb, Roche, Toyota, Uber
10:48aWALL STREET STOCK EXCHANGE : Snap cut the rally short
09:26aRubius Therapeutics Names Noubar Afeyan Chairman; Shares Rise Pre-Bell
09:15aTRANSCRIPT : Moderna, Inc. Presents at UBS Global Healthcare Conference, May-24-2022 09:15..
08:03aMODERNA, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
07:44aModerna testing potential monkeypox vaccines
06:41aModerna CEO to Exercise 2013 Option, Donate Funds to Charity
01:08aChina's bet on homegrown mRNA vaccines holds back nation
05/23MODERNA : Statement Regarding Section 1498 Motion
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2022 22 069 M - -
Net income 2022 11 501 M - -
Net cash 2022 18 081 M - -
P/E ratio 2022 4,85x
Yield 2022 -
Capitalization 52 528 M 52 528 M -
EV / Sales 2022 1,56x
EV / Sales 2023 3,16x
Nbr of Employees 2 700
Free-Float 90,6%
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 132,06 $
Average target price 212,69 $
Spread / Average Target 61,1%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-48.00%54 740
LONZA GROUP AG-27.15%42 618
IQVIA HOLDINGS INC.-28.41%38 497
SEAGEN INC.-13.67%25 649
CELLTRION, INC.-26.77%16 131